Therapeutic potential of chloroquine added to zidovudine plus didanosine for HIV-1 infected children

Journal of the Medical Association of Thailand

Volumn 89, Issue 8, 2006, Pages 1229-1236

  Engchanil, Chulapan ^a   Kosalaraksa, Pope ^a   Lumbiganon, Pagakrong ^a   Lulitanond, Viraphong ^a   Pongjunyakul, Piyaporn ^b   Thuennadee, Ruengsin ^c   Tungsawad, Sasithorn ^c   Suwan Apichon, Olan ^a  

^a KHON KAEN UNIVERSITY   (Thailand)

^b Northeast Regional Hospital for Infectious Diseases

^c Region 6 Communicable Disease Control   (Thailand)

Author keywords

Chloroquine; HIV 1 infected children; Zidovudine plus Didanosine

Indexed keywords

CHLOROQUINE; DIDANOSINE; DIDANOSINE PLUS ZIDOVUDINE; UNCLASSIFIED DRUG; ZIDOVUDINE;

ANEMIA; CD4+ T LYMPHOCYTE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION; MAJOR CLINICAL STUDY; NAUSEA; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; RASH; SCORING SYSTEM; THROMBOCYTOPENIA; VOMITING;

ANTI-HIV AGENTS; ANTIMALARIALS; CHILD; CHILD, PRESCHOOL; CHLOROQUINE; DIDANOSINE; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; ZIDOVUDINE;

EID: 33748483487     PISSN: 01252208     EISSN: 01252208     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (26)

1. Englund JA, Baker CJ, Raskino C, McKinney RE, Petrie B, Fowler MG, et al. Zidovudine, didanosine, or both as the initial treatment for symptomatic HIV-infected children. AIDS Clinical Trials Group (ACTG) Study 152 Team. N Engl J Med 1997; 336: 1704-12.
2. McKinney RE Jr, Johnson GM, Stanley K, Yong FH, Keller A, O'Donnell KJ, et al. A randomized study of combined zidovudine-lamivudine versus didanosine monotherapy in children with symptomatic therapy-naive HIV-1 infection. The Pediatric AIDS Clinical Trials Group Protocol 300 Study Team. J Pediatr 1998; 133: 500-8.
3. Mofenson LM, Korelitz J, Meyer WA III, Bethel J, Rich K, Pahwa S, et al. The relationship between serum human immunodeficiency virus type 1 (HIV-1) RNA level, CD4 lymphocyte percent, and long-term mortality risk in HIV-1-infected children. National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group. J Infect Dis 1997; 175: 1029-38.
4. Guidelines for the use of antiretroviral agents in pediatric HIV infection. Centers for Disease Control and Prevention. MMWR Recomm Rep 1998; 47: 1-43.
5. Boelaert JR, Sperber K, Piette J. Chloroquine exerts an additive in vitro anti-HIV type 1 effect when associated with didanosine and hydroxyurea. AIDS Res Hum Retroviruses 1999; 15: 1241-7.
6. Chiang G, Sassaroli M, Louie M, Chen H, Stecher VJ, Sperber K. Inhibition of HIV-1 replication by hydroxychloroquine: mechanism of action and comparison with zidovudine. Clin Ther 1996; 18: 1080-92.
7. Gottlieb RA, Nordberg J, Skowronski E, Babior BM. Apoptosis induced in Jurkat cells by several agents is preceded by intracellular acidification. Proc Natl Acad Sci U S A 1996; 93: 654-8.
8. Jiang MC, Lin JK, Chen SS. Inhibition of HIV-1 Tat-mediated transactivation by quinacrine and chloroquine. Biochem Biophys Res Commun 1996; 226: 1-7.
9. Meng XW, Feller JM, Ziegler JB, Pittman SM, Ireland CM. Induction of apoptosis in peripheral blood lymphocytes following treatment in vitro with hydroxychloroquine. Arthritis Rheum 1997; 40: 927-35.
10. Ornstein MH, Sperber K. The antiinflammatory and antiviral effects of hydroxychloroquine in two patients with acquired immunodeficiency syndrome and active inflammatory arthritis. Arthritis Rheum 1996; 39: 157-61.
11. Sperber K, Chiang G, Chen H, Ross W, Chusid E, Gonchar M, et al. Comparison of hydroxychloroquine with zidovudine in asymptomatic patients infected with human immunodeficiency virus type 1. Clin Ther 1997; 19: 913-23.
12. Sperber K, Kalb TH, Stecher VJ, Banerjee R, Mayer L. Inhibition of human immunodeficiency virus type 1 replication by hydroxychloroquine in T cells and monocytes. AIDS Res Hum Retroviruses 1993; 9: 91-8.
13. Tsai WP, Nara PL, Kung HF, Oroszlan S. Inhibition of human immunodeficiency virus infectivity by chloroquine. AIDS Res Hum Retroviruses 1990; 6: 481-9.
14. Wolvetang EJ, Larm JA, Moutsoulas P, Lawen A. Apoptosis induced by inhibitors of the plasma membrane NADH-oxidase involves Bcl-2 and calcineurin. Cell Growth Differ 1996; 7: 1315-25.
15. Sperber K, Quraishi H, Kalb TH, Panja A, Stecher V, Mayer L. Selective regulation of cytokine secretion by hydroxychloroquine: inhibition of interleukin 1 alpha (IL-1-alpha) and IL-6 in human monocytes and T cells. J Rheumatol 1993; 20: 803-8.
16. Sperber K, Louie M, Kraus T, Proner J, Sapira E, Lin S, et al. Hydroxychloroquine treatment of patients with human immunodeficiency virus type 1. Clin Ther 1995; 17: 622-36.
17. Neely M, Kalyesubula I, Bagenda D, Myers C, Olness K. Effect of chloroquine on human immunodeficiency virus (HIV) vertical transmission. Afr Health Sci 2003; 3: 61-7.
18. Kalyesubula I, Musoke-Mudido P, Marum L, Bagenda D, Aceng E, Ndugwa C, et al. Effects of malaria infection in human immunodeficiency virus type 1-infected Ugandan children. Pediatr Infect Dis J 1997; 16: 876-81.
19. Pattanapanyasat K, Kyle DE, Tongtawe P, Yongvanitchit K, Fucharoen S. Flow cytometric immunophenotyping of lymphocyte subsets in samples that contain a high proportion of non-lymphoid cells. Cytometry 1994; 18: 199-208.
20. Chaulet JF, Robet Y, Prevosto JM, Soares O, Brazier JL. Simultaneous determination of chloroquine and quinine in human biological fluids by high-performance liquid chromatography. J Chromatogr 1993; 613: 303-10.
21. Husson RN, Mueller BU, Farley M, Woods L, Kovacs A, Goldsmith JC, et al . Zidovudine and didanosine combination therapy in children with human immunodeficiency virus infection. Pediatrics 1994; 93: 316-22.
22. de Mendoza C, Ramos JT, Ciria L, Fortuny C, Garcia FJ, de Jose MI, et al. Efficacy and safety of stavudine plus didanosine in asymptomatic HIV-infected children with plasma HIV RNA below 50,000 copies per milliliter. HIV Clin Trials 2002; 3: 9-16.
23. th ed. New York: McGraw-Hill; 1996: 965-86.
24. Walker O, Dawodu AH, Adeyokunnu AA, Salako LA, Alvan G. Plasma chloroquine and desethylchloroquine concentrations in children during and after chloroquine treatment for malaria. Br J Clin Pharmacol 1983; 16: 701-5.
25. Nishimura M, Hidaka N, Akaza T, Tadokoro K, Juji T. Immunosuppressive effects of chloroquine: potential effectiveness for treatment of post-transfusion graft-versus-host disease. Transfus Med 1998; 8: 209-14.
26. Salmeron G, Lipsky PE. Immunosuppressive potential of antimalarials. Am J Med 1983; 75: 19-24.